看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | -3.5x - -3.8x | -3.7x |
| Selected Fwd EBITDA Multiple | -6.7x - -7.4x | -7.1x |
| Fair Value | $9.92 - $11.17 | $10.55 |
| Upside | -20.4% - -10.4% | -15.4% |
| Benchmarks | Ticker | Full Ticker |
| Sangamo Therapeutics, Inc. | SGMO | NasdaqCM:SGMO |
| Merus N.V. | MRUS | NasdaqGM:MRUS |
| LAVA Therapeutics N.V. | LVTX | NasdaqGS:LVTX |
| Pharming Group N.V. | PHGU.F | OTCPK:PHGU.F |
| NewAmsterdam Pharma Company N.V. | NAMS | NasdaqGM:NAMS |
| uniQure N.V. | QURE | NasdaqGS:QURE |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| SGMO | MRUS | LVTX | PHGU.F | NAMS | QURE | ||
| NasdaqCM:SGMO | NasdaqGM:MRUS | NasdaqGS:LVTX | OTCPK:PHGU.F | NasdaqGM:NAMS | NasdaqGS:QURE | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | -36.5% | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | -37.4% | NM- | NM- | |
| Latest Twelve Months | 6.0% | -75.1% | 31.5% | 148.7% | 3.7% | 32.9% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -235.0% | -335.8% | -453.6% | 14.0% | -848.2% | -650.5% | |
| Prior Fiscal Year | -56.3% | -350.4% | -629.9% | -6.2% | -1298.2% | -1593.9% | |
| Latest Fiscal Year | -161.3% | -746.1% | -243.6% | 2.5% | -386.7% | -624.8% | |
| Latest Twelve Months | -161.3% | -746.1% | -243.6% | 2.5% | -386.7% | -624.8% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.99x | 65.54x | -3.12x | 1.79x | 34.15x | 28.77x | |
| EV / LTM EBITDA | -1.9x | -8.8x | 1.3x | 71.3x | -8.8x | -4.6x | |
| EV / LTM EBIT | -1.8x | -8.7x | 1.3x | -61.6x | -8.8x | -4.3x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -8.8x | -1.9x | 71.3x | ||||
| Historical EV / LTM EBITDA | -10.0x | -4.6x | 1.6x | ||||
| Selected EV / LTM EBITDA | -3.5x | -3.7x | -3.8x | ||||
| (x) LTM EBITDA | (169) | (169) | (169) | ||||
| (=) Implied Enterprise Value | 588 | 619 | 650 | ||||
| (-) Non-shareholder Claims * | (106) | (106) | (106) | ||||
| (=) Equity Value | 482 | 513 | 544 | ||||
| (/) Shares Outstanding | 54.1 | 54.1 | 54.1 | ||||
| Implied Value Range | 8.91 | 9.48 | 10.05 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 8.91 | 9.48 | 10.05 | 12.47 | |||
| Upside / (Downside) | -28.5% | -24.0% | -19.4% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | SGMO | MRUS | LVTX | PHGU.F | NAMS | QURE | |
| Enterprise Value | 173 | 2,368 | (37) | 618 | 1,556 | 780 | |
| (+) Cash & Short Term Investments | 42 | 537 | 77 | 168 | 834 | 368 | |
| (+) Investments & Other | 0 | 187 | 0 | 4 | 0 | 27 | |
| (-) Debt | (31) | (10) | (5) | (112) | (0) | (501) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 184 | 3,082 | 34 | 678 | 2,390 | 674 | |
| (/) Shares Outstanding | 224.7 | 69.1 | 26.3 | 752.8 | 109.8 | 54.1 | |
| Implied Stock Price | 0.82 | 44.61 | 1.29 | 0.90 | 21.76 | 12.47 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.82 | 44.61 | 1.29 | 0.90 | 21.76 | 12.47 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |